Cervical Cancer Screening Market: By Test Type (Pap Smear Tests, HPV Tests, LBC Tests, Others), and Geography

Purchase Option

$ 4400
$ 6600
$ 8900

Cervical Cancer Screening Market size was valued at USD 9,210.4 million in 2023 and is poised to grow at a significant CAGR of 5.4% over 2024-2030. An increase in the prevalence of cervical cancer due to the surge in the global female population is a considerable factor surge the growth of the cervical cancer screening market over the forecast years. Moreover, raising awareness about cancer diseases among people in developed countries, the surge in demand for early-stage disease diagnosis, and favorable reimbursement policies are enhancing the market's revenue.

Cervical Cancer Screening Market

In addition, the increase in consumption of tobacco and alcohol among the female population, the surge in the prevalence of HPV infection, increase in the incidence of unsafe sex also boost the market over the forecast timeframe. The development of newer tests to diagnose cervical cancer more efficiently the expansion of the business into low-income markets and the high prevalence of cervical cancer countries create some opportunities for marketers. In the cervical cancer screening market, the pap smear tests segment is estimated to lead the global cervical cancer screening market in 2022, in terms of value and volume, owing to increased government funding and insurance coverage.

Cervical Cancer Screening Market Key Developments:
  • In February 2023, the US FDA approved the BD Onclarity™ HPV Assay. BD has a stronghold in cervical cancer screening, and the approval of its HPV assay will further strengthen its portfolio. As per the company source, the BD Onclarity™ HPV Assay is the only assay that detects and identifies 14 high-risk human papillomavirus (HPV) types in a single run.
  • In March 2023, The BD Onclarity™ HPV Assay was incorporated into the NHS Cervical cancer screening program, which can be viewed as a big win for the company. The assay allows for at-home collection of vaginal swab samples making it more convenient, easy, accessible, and potentially less uncomfortable for women compared to clinician-taken cervical samples.
  • In November 2023, Abbott received the US FDA approval for its Alinity m high risk (HR) HPV assay. This will add the assay to their molecular diagnostics portfolio. The assay can be used alongside the Pap test.
  • In November 2020, Hologic, Inc. announced that its new Genius Digital Diagnostics System is CE-marked in Europe. Genius Digital Diagnostics is the first digital cytology platform to combine a new artificial intelligence (AI) algorithm with advanced digital imaging to help cytotechnologists and pathologists identify pre-cancerous lesions and cancer cells in women.

Cervical Cancer Screening Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

5.4%

Largest Market

North America

Fastest Growing Market

North America
Cervical Cancer Screening Market Dynamics

The global cervical cancer screening market is mainly driven by the increased prevalence of cervical cancer cases and fundraising for cervical cancer screening programs. Changes in the screening criteria, screening rates, lack of awareness about cervical cancer, and adoption of alternate testing procedures will hinder the market growth.

Cervical Cancer Screening Market Segmentation

By Test Type
  • Pap Smear Tests
  • HPV Tests
  • LBC Tests
  • Others
By Geography
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • MEA

Frequently Asked Questions

The cervical cancer screening market is projected to expand at a CAGR of 5.4% during the forecast period.

Abbott., Hologic, Inc., QIAGEN, Hoffmann-La Roche Ltd, Quest Diagnostics Incorporated.

North America and Asia-Pacific is the fastest-growing cervical cancer screening market

Key Features of the Reports

  • The cervical cancer screening market report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
1.Executive Summary
2.Global Cervical Cancer Screening Market Introduction 
2.1.Global Cervical Cancer Screening Market  - Taxonomy
2.2.Global Cervical Cancer Screening Market  - Definitions
2.2.1. By Test Type
2.2.2. By Region
3.Global Cervical Cancer Screening Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4.Global Cervical Cancer Screening Market Analysis, 2019 - 2023 and Forecast 2024 - 2030
4.1.  Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Cervical Cancer Screening Market  By Test Type, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
5.1. Pap Smear Tests
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. HPV Tests
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. LBC Tests
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
5.4. Others
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.4.3. Market Opportunity Analysis 
6.Global Cervical Cancer Screening Market  By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
6.1. North America
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Europe
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Asia Pacific (APAC)
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
6.4. Middle East and Africa (MEA)
6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.4.3. Market Opportunity Analysis 
6.5. Latin America
6.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.5.3. Market Opportunity Analysis 
7.North America Cervical Cancer Screening Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
7.1. Test Type Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
7.1.1.Pap Smear Tests
7.1.2.HPV Tests
7.1.3.LBC Tests
7.1.4.Others
7.2.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
7.2.1.United States of America (USA)
7.2.2.Canada
8.Europe Cervical Cancer Screening Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
8.1. Test Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
8.1.1.Pap Smear Tests
8.1.2.HPV Tests
8.1.3.LBC Tests
8.1.4.Others
8.2.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
8.2.1.Germany
8.2.2.France
8.2.3.Italy
8.2.4.United Kingdom (UK)
8.2.5.Spain
9.Asia Pacific (APAC) Cervical Cancer Screening Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
9.1. Test Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.Pap Smear Tests
9.1.2.HPV Tests
9.1.3.LBC Tests
9.1.4.Others
9.2.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.China
9.2.2.India
9.2.3.Australia and New Zealand (ANZ)
9.2.4.Japan
9.2.5.Rest of APAC
10.Middle East and Africa (MEA) Cervical Cancer Screening Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
10.1. Test Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Pap Smear Tests
10.1.2.HPV Tests
10.1.3.LBC Tests
10.1.4.Others
10.2.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.GCC Countries
10.2.2.South Africa
10.2.3.Rest of MEA
11.Latin America Cervical Cancer Screening Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
11.1. Test Type Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Pap Smear Tests
11.1.2.HPV Tests
11.1.3.LBC Tests
11.1.4.Others
11.2.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Brazil
11.2.2.Mexico
11.2.3.Rest of LA
12. Competition Landscape
12.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
12.2.1.Hologic, Inc.
12.2.2.Abbott,
12.2.3.QIAGEN
12.2.4.Hoffmann-La Roche Ltd
12.2.5.Quest Diagnostics Incorporated.
12.2.6.Becton, Dickinson, and Company
12.2.7.Cooper Surgical Inc.,
12.2.8.Arbor Vita Corporation,
13. Research Methodology 
14. Appendix and Abbreviations 
  • Hologic, Inc.
  • Abbott,
  • QIAGEN
  • Hoffmann-La Roche Ltd
  • Quest Diagnostics Incorporated.
  • Becton, Dickinson, and Company
  • Cooper Surgical Inc.,
  • Arbor Vita Corporation,

Adjacent Markets